Cargando…

A novel mechanism of inhibiting in-stent restenosis with arsenic trioxide drug-eluting stent: Enhancing contractile phenotype of vascular smooth muscle cells via YAP pathway

OBJECTIVE: Arsenic trioxide (ATO or As(2)O(3)) has beneficial effects on suppressing neointimal hyperplasia and restenosis, but the mechanism is still unclear. The goal of this study is to further understand the mechanism of ATO's inhibitory effect on vascular smooth muscle cells (VSMCs). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yinping, Zang, Guangchao, Yin, Tieying, Ma, Xiaoyi, Zhou, Lifeng, Wu, Lingjuan, Daniel, Richard, Wang, Yunbing, Qiu, Juhui, Wang, Guixue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	KeAi Publishing 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7484501/ https://www.ncbi.nlm.nih.gov/pubmed/32954055 http://dx.doi.org/10.1016/j.bioactmat.2020.08.018

Ejemplares similares

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
por: Dinesch, Violeta, et al.
Publicado: (2017)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Therapeutic Strategy for In-Stent Restenosis Based on the Restenosis Pattern After Drug-Eluting Stent Implantation
por: Kim, Ki-Hun, et al.
Publicado: (2009)

Response to drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
Publicado: (2017)

Anti-Inflammatory Effects of Arsenic Trioxide Eluting Stents in a Porcine Coronary Model
por: Shen, Li, et al.
Publicado: (2013)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Effects of a Matrix Metalloproteinase Inhibitor-Eluting Stent on In-Stent Restenosis
por: Song, Jian-bo, et al.
Publicado: (2020)

Distinctive effects of CD34- and CD133-specific antibody-coated stents on re-endothelialization and in-stent restenosis at the early phase of vascular injury
por: Wu, Xue, et al.
Publicado: (2015)

In-Stent Restenosis due to Stent Recoil After Third-Generation Drug-Eluting Stent Implantation
por: Kato, Yuta, et al.
Publicado: (2017)

Predictors of diffuse-type in-stent restenosis following drug-eluting stent implantation
por: PARK, CHANG-BUM, et al.
Publicado: (2013)

Stent Thrombosis and Restenosis with Contemporary Drug-Eluting Stents: Predictors and Current Evidence
por: Condello, Francesco, et al.
Publicado: (2023)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Intravascular Ultrasound-Guided Treatment for In-stent Restenosis Associated with Stent Fracture in Overlapped Drug-eluting Stents
por: Kim, Min Chul, et al.
Publicado: (2019)

Drug-eluting stents or balloon angioplasty for drug-eluting stent-associated restenosis: An observational follow-up study of first-time versus repeated restenosis
por: Abdelmegid, Mohamed Aboel-Kassem F., et al.
Publicado: (2017)

Genetic risk model for in-stent restenosis of second-and third-generation drug-eluting stents
por: Liu, Yen-Wen, et al.
Publicado: (2021)

Drug‐Eluting Stent Targeting Sp‐1‐Attenuated Restenosis by Engaging YAP‐Mediated Vascular Smooth Muscle Cell Phenotypic Modulation
por: Huang, Chen, et al.
Publicado: (2019)

The efficacy and safety of drug-eluting balloons for the treatment of in-stent restenosis as compared with drug-eluting stents and with conventional balloon angioplasty
por: Oh, Pyung Chun, et al.
Publicado: (2016)

Reduction of In-Stent Restenosis and Inflammation with One Stent: New Concept of Sirolimus and Ascorbic Acid-Eluting Coronary Stent
por: Ryu, JiWung, et al.
Publicado: (2021)

Impact of Exercise-based Cardiac Rehabilitation on In-stent Restenosis with Different Generations of Drug Eluting Stent
por: Kim, Chul, et al.
Publicado: (2012)

Local drug-delivery balloon for proliferative occlusive in-stent restenosis after drug-eluting stent
por: Rigatelli, Gianluca, et al.
Publicado: (2011)

Inverse Relationship between Serum VEGF Levels and Late In-Stent Restenosis of Drug-Eluting Stents
por: Yin, Jiasheng, et al.
Publicado: (2017)

In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario
por: Paramasivam, Ganesh, et al.
Publicado: (2019)

Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation
por: Luo, Yinhua, et al.
Publicado: (2022)

State-of-the-Art Stent Technology to Minimize the Risk of Stent Thrombosis and In-Stent Restenosis: Abluminal-Coated Biodegradable Polymer Drug-Eluting Stent
por: Kang, Dong Oh, et al.
Publicado: (2022)

Multiple Sequential Complications After Sirolimus-Eluting Stent Implantation: Very Late Stent Thrombosis, Stent Fracture, In-Stent Restenosis, and Peri-Stent Aneurysm
por: Seol, Sang-Hoon, et al.
Publicado: (2009)

Inhibition of in-stent restenosis after graphene oxide double-layer drug coating with good biocompatibility
por: Ge, Shuang, et al.
Publicado: (2019)

Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis
por: Yin, Rui-Xing, et al.
Publicado: (2014)

Value of S100A12 in predicting in-stent restenosis in patients with coronary drug-eluting stent implantation
por: Liang, Hengyi, et al.
Publicado: (2020)

The Predictors of Target Lesion Revascularization and Rate of In-Stent Restenosis in the Second-Generation Drug-Eluting Stent Era
por: Zheng, Chengbin, et al.
Publicado: (2019)

In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes
por: Paramasivam, Ganesh, et al.
Publicado: (2020)

Nine-month Angiographic and Two-year Clinical Follow-up of Novel Biodegradable-polymer Arsenic Trioxide-eluting Stent Versus Durable-polymer Sirolimus-eluting Stent For Coronary Artery Disease
por: Shen, Li, et al.
Publicado: (2015)

Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis
por: Cui, Kong-Yong, et al.
Publicado: (2018)

Drug-eluting balloons versus new generation drug-eluting stents for the management of in-stent restenosis: an updated meta-analysis of randomized studies
por: Gao, Lei, et al.
Publicado: (2019)

Combining short stent implantation and drug-eluting stenting for routine use yields a low restenosis rate
por: Dietz, Ulrich, et al.
Publicado: (2005)

In-Stent Restenosis Exacerbated by Drug-Induced Severe Eosinophilia after Second-Generation Drug-Eluting Stent Implantation
por: Yagi, Hiroki, et al.
Publicado: (2014)

Impact of the Distance from the Stent Edge to the Residual Plaque on Edge Restenosis following Everolimus-Eluting Stent Implantation
por: Takahashi, Masao, et al.
Publicado: (2015)

Effect of diabetes mellitus on long-term outcomes after repeat drug-eluting stent implantation for in-stent restenosis
por: Zhao, Lin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4n9ju1m6u211f3uncqt4d4029i